^
    21d
    MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma (clinicaltrials.gov)
    P1/2, N=264, Recruiting, Perspective Therapeutics | Trial completion date: Jun 2027 --> Dec 2029 | Trial primary completion date: Jun 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • VMT-01
    2ms
    MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma (clinicaltrials.gov)
    P1/2, N=264, Recruiting, Perspective Therapeutics | N=52 --> 264
    Enrollment change • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • VMT-01
    over1year
    MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma (clinicaltrials.gov)
    P1/2, N=52, Recruiting, Viewpoint Molecular Targeting | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    VMT-01
    over1year
    MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma (clinicaltrials.gov)
    P1/2, N=52, Not yet recruiting, Viewpoint Molecular Targeting | Initiation date: Dec 2022 --> Jun 2023
    Trial initiation date
    |
    BRAF (B-raf proto-oncogene)
    |
    VMT-01
    almost2years
    MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma (clinicaltrials.gov)
    P1/2, N=52, Not yet recruiting, Viewpoint Molecular Targeting
    New P1/2 trial • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    VMT-01
    over3years
    Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma. (PubMed, Cancers (Basel))
    Enhanced tumor infiltrating CD3, CD4, CD8 lymphocytes were observed following injection of 1.4 MBq [Pb]VMT01. Overall, we demonstrated anti-tumor cooperation between α-TRT and ICIs in melanoma that is mediated by tumor specific immunity.
    Journal • Checkpoint inhibition
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    VMT-01